HOME
SEARCH
RSS FEED
SUBSCRIBE
Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma
Case ID:
TAB-188
Web Published:
12/6/2022
Description:
The technology offered for licensing is in the field of Therapeutics. More specifically, the technology relates to biological ligands and their use as modulators of the production of Interferon gamma as a means to treat a broad spectrum of diseases. The invention describes and claims antibodies and other ligands that can stimulate Natural Killer (NK) immune cells to produce Interferon gamma which contributes to the combat against foreign pathogens. Conversely, the invention also describes and claims methods that can inhibit such Interferon gamma production for treatment of diseases where excess of Interferon is not desirable. The invention also describes methods and assays to identify both inducing and inhibiting ligands
The license agreement may include biological materials, such as monoclonal antibodies that were made and identified by the inventors as Interferon gamma stimulators.
Interferon-gamma is a potent antiviral and antimicrobial substance produced by natural killer (NK) white blood cells. NK cells are activated during infections by viruses and by other intracellular pathogens, such as parasites and bacteria. Soluble substances, such as interleukins, produced by infected cells activate NK cells to secrete interferon-gamma. Injection of interleukins into patients to stimulate NK cells to secrete interferon-gamma has not been a successful therapeutic approach because of the toxicity involved. The invention is based on the discovery by the inventors that activation of the KIR2DL4 receptor expressed by all NK cells stimulates them to produce interferon-gamma. The invention claims monoclonal antibodies and derivatives thereof, as well as natural and synthetic ligands of KIR2DL4 that can be utilized to stimulate interferon-gamma production by NK cells without any other stimulus. The possibility of inducing interferon-gamma production by NK cells without the toxic side effects of interleukins could be an effective therapy for various types of infections and of cancers. Also claimed in the invention are methods of treating various cancers and viral infections, methods of treating autoimmune disease, and methods of administration of the antibody or derivatives thereof. Certain diseases benefit from reduction in the amount of Interferon gamma. The instant invention claims such ligands that are capable of inhibiting KIR2DL4 from producing interferon gamma. It also describes methods of identifying such ligands.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Therapeutic_Methods_Based_on_In_Vivo _Modulation_of_the_Production_of_Interferon_gamma
Category(s):
Licensing
Therapeutics
Infectious Disease
Vaccines
Bookmark this page
Download as PDF
For Information, Contact:
Dawn Taylor-Mulneix
TTPS
NIH Technology Transfer
301-761-6958
dawn.taylor-mulneix@nih.gov
Inventors:
Sumati (Sumi) Rajagopalan
Eric Long
Keywords:
Against
antibodies
DB3XXX
DB4XXX
DBXXXX
DC1XXX
DCXXXX
Directed
DXXXXX
Gamma
INTERFERON
KIR2DL4
LIGANDS
Patent Category - Biotechnology
production
RECEPTOR
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum